2025/06/30 by Wei Xu, Danping Liu, Renfang Zhang +2 · 1 voice
Medicine · #HIV-related health complications and treatments #Hepatitis C virus research #Liver Disease Diagnosis and Treatment
paper · doi:10.1093/ofid/ofaf369
openalex publication_date 2025/06/30 · openalex created_date 2025/10/10 · openalex updated_date 2026/06/18
Background: We aimed to investigate the prevalence of liver fibrosis and identify the associated risk factors among people with HIV (PWH) and metabolic dysfunction-associated steatotic liver disease (MASLD). Methods: . A cutoff of liver stiffness measurement ≥ 7.1 kPa was set for significant liver fibrosis. The prevalence, correlation factors, and risk factors were evaluated. Results: , and 141 (39.06%) were diagnosed with MASLD. The 141 PWH with MASLD were classified as 2 groups based on BMI: 58 (41.13%) as lean MASLD and 83 (58.87%) as overweight MASLD. Significant fibrosis was observed in 121 of the 361 PWH, including 75 of the 141 with MASLD, 28 of the 58 with lean MASLD, and 47 of the 83 with overweight MASLD. Among PWH with MASLD, independent risk factors for significant liver fibrosis included higher alanine aminotransferase levels and the presence of type 2 diabetes. Among PWH with lean MASLD, independent risk factors for significant liver fibrosis included elevated aspartate aminotransferase levels and the administration of non-nucleoside reverse transcriptase inhibitors. Conclusions: Significant liver fibrosis is highly prevalent among PWH and MASLD. Multiple risk factors are associated with significant liver fibrosis among PWH. These findings underscore the importance of early identification and management of liver fibrosis in PWH. Clinical Trials Registration: NCT04215926.